Comparative Pharmacology
Head-to-head clinical analysis: HC 4 versus LIDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HC 4 versus LIDEX.
HC #4 vs LIDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HC #4 is a complex homeopathic preparation with no well-defined molecular mechanism; it is believed to act via hormesis or placebo effects.
Glucocorticoid receptor agonist; inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis; suppresses inflammatory cytokines and immune cell migration.
Hydrocortisone 100-300 mg IV bolus, followed by 100-200 mg IV every 6 hours for 24-48 hours; then taper as clinically indicated.
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Terminal elimination half-life: 12 hours (range 10–14 hours). Extends to 24 hours in severe renal impairment (CrCl <30 mL/min); dose adjustment recommended.
Terminal elimination half-life: 28-36 hours. Clinical context: Steady-state achieved in ~5-7 days; once-daily dosing maintains therapeutic levels without accumulation in patients with normal renal function.
Renal excretion of unchanged drug: 95%; fecal/biliary: <5%.
Renal (primarily as metabolites) ~ 95%; biliary/fecal ~5%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid